Net income
-106 million USD
2025-07-01 – 2026-06-30
Fundies. English
Enliven Therapeutics, Inc.
EDGAR55 filing records in this dataset, filed from 2020-02-14 to 2026-10-14. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 136 million USD Source
Exact value
135505000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 73.3 million shares Source
Exact value
73251648 shares
Reported share-count change
23.68% · 14 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-66.9 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -54463000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -41184000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -70301000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -54463000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -19291000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -37822000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -19291000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 7 of 11 periods available· newest 2025-12-31
- Net income: 7 of 11 periods available· newest 2025-12-31
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 7 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2025-12-31
- Current assets: 7 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 7 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 14.67 millionPrior period
−USD 89.02 million
–
Current period
−USD 103.69 million
–
Exact inputs and evidence
-103694000 − -89024000 = -14670000 USD
-89024000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-103694000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.89 millionPrior period
−USD 73.19 million
–
Current period
−USD 70.3 million
–
Exact inputs and evidence
-70301000 − -73192000 = 2891000 USD
-73192000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-70301000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2019 2019-01-01 – 2019-12-31 | −USD 23.46 million Exact valueExact value: -23463000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 21.88 million Exact valueExact value: -21877000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | −USD 41.36 million Exact valueExact value: -41360000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 37.4 million Exact valueExact value: -37398000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 51.38 million Exact valueExact value: -51384000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 46.77 million Exact valueExact value: -46771000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 37.66 million Exact valueExact value: -37662000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 32.08 million Exact valueExact value: -32077000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 71.58 million Exact valueExact value: -71584000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 61.27 million Exact valueExact value: -61269000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 89.02 million Exact valueExact value: -89024000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 73.19 million Exact valueExact value: -73192000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 103.69 million Exact valueExact value: -103694000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 70.3 million Exact valueExact value: -70301000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
55 filings · 1,504 latest values · 1,504 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001672619, 1672619, ELVN, IMRA, edgar:1672619
Also known as ENLIVEN THERAPEUTICS, INC., Enliven Therapeutics, Inc., IMARA INC., IMARA Inc., IMARA INC.